Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Cape Investment Advisory Inc.

Cape Investment Advisory Inc. lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.0% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 795 shares of the biopharmaceutical company’s stock after selling 199 shares during the period. Cape Investment Advisory Inc.’s holdings in Gilead Sciences were worth $58,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Keynote Financial Services LLC acquired a new position in Gilead Sciences during the 1st quarter worth about $845,000. IMS Capital Management lifted its position in shares of Gilead Sciences by 34.8% during the first quarter. IMS Capital Management now owns 6,623 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 1,710 shares in the last quarter. Railway Pension Investments Ltd boosted its stake in shares of Gilead Sciences by 0.3% in the first quarter. Railway Pension Investments Ltd now owns 1,563,965 shares of the biopharmaceutical company’s stock valued at $114,560,000 after purchasing an additional 4,800 shares during the period. Cetera Advisors LLC grew its holdings in shares of Gilead Sciences by 167.2% in the first quarter. Cetera Advisors LLC now owns 82,786 shares of the biopharmaceutical company’s stock valued at $6,064,000 after purchasing an additional 51,801 shares in the last quarter. Finally, Cetera Investment Advisers grew its holdings in shares of Gilead Sciences by 127.6% in the first quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after purchasing an additional 119,909 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $0.28 during midday trading on Friday, hitting $76.77. The stock had a trading volume of 6,458,108 shares, compared to its average volume of 6,392,589. The company has a market capitalization of $95.64 billion, a PE ratio of 213.25, a P/E/G ratio of 3.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The stock has a 50 day moving average price of $68.80 and a two-hundred day moving average price of $70.77. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31.

Analyst Ratings Changes

Several equities analysts have commented on GILD shares. TD Cowen dropped their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Maxim Group cut their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. UBS Group cut their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Finally, Cantor Fitzgerald reduced their target price on shares of Gilead Sciences from $75.00 to $70.00 and set a “neutral” rating on the stock in a report on Monday, July 22nd. Twelve research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and a consensus target price of $81.81.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.